These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 38532478)

  • 1. Towards mission-driven investment in new antimicrobials? What role for Chinese strategic industrial financing vehicles in responding to the challenge of antimicrobial resistance?
    Husain L; Hu Y; Huang Y
    Global Health; 2024 Mar; 20(1):26. PubMed ID: 38532478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The challenge of healthcare big data to China's commercial health insurance industry: evaluation and recommendations.
    Wu J; Qiao J; Nicholas S; Liu Y; Maitland E
    BMC Health Serv Res; 2022 Sep; 22(1):1189. PubMed ID: 36138390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upgrading Big Brother: Local Strategic Adaptation in China's Security Industry.
    Huang J; Tsai KS
    Stud Comp Int Dev; 2021; 56(4):560-587. PubMed ID: 34629564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic Incentives for Antibacterial Drug Development: Literature Review and Considerations From the Transatlantic Task Force on Antimicrobial Resistance.
    Sciarretta K; Røttingen JA; Opalska A; Van Hengel AJ; Larsen J
    Clin Infect Dis; 2016 Dec; 63(11):1470-1474. PubMed ID: 27578820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding China's growing involvement in global health and managing processes of change.
    Husain L; Bloom G
    Global Health; 2020 May; 16(1):39. PubMed ID: 32357894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can public financing of the private sector defeat antimicrobial resistance?
    James JE
    J Public Health (Oxf); 2019 Jun; 41(2):422-426. PubMed ID: 29982521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Industrial Investment Funds, Government R&D Subsidies, and Technological Innovation: Evidence From Chinese Companies.
    Ren YM
    Front Psychol; 2022; 13():890208. PubMed ID: 35774961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The global governance of antimicrobial resistance: a cross-country study of alignment between the global action plan and national action plans.
    Munkholm L; Rubin O
    Global Health; 2020 Nov; 16(1):109. PubMed ID: 33176810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Executive pharmaceutical background, R&D investment and corporate innovation performance.
    Zhang L; Li S; Wu M
    Am J Transl Res; 2023; 15(11):6576-6586. PubMed ID: 38074834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. To Push or To Pull? In a Post-COVID World, Supporting and Incentivizing Antimicrobial Drug Development Must Become a Governmental Priority.
    Cama J; Leszczynski R; Tang PK; Khalid A; Lok V; Dowson CG; Ebata A
    ACS Infect Dis; 2021 Aug; 7(8):2029-2042. PubMed ID: 33606496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of "industry policy" and "financial institution" configuration effect on innovation performance of China's biomedical industry-based on necessary condition analysis and qualitative comparative analysis.
    Zhang Y
    Front Med (Lausanne); 2023; 10():1297495. PubMed ID: 38259851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of China's and the European Union's Approaches to Antimicrobial Stewardship in the Pork Industry.
    Lim MSM; Grohn YT
    Foodborne Pathog Dis; 2021 Aug; 18(8):567-573. PubMed ID: 33794668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unpacking multi-level governance of antimicrobial resistance policies: the case of Guangdong, China.
    Chan OSK; Wernli D; Liu P; Tun HM; Fukuda K; Lam W; Xiao Y; Zhou X; Grépin KA
    Health Policy Plan; 2022 Oct; 37(9):1148-1157. PubMed ID: 35775460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does China's national volume-based drug procurement policy promote or hinder pharmaceutical innovation?
    Li X; Xu J
    Front Pharmacol; 2024; 15():1392239. PubMed ID: 38994196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incentivising innovation in antibiotic drug discovery and development: progress, challenges and next steps.
    Simpkin VL; Renwick MJ; Kelly R; Mossialos E
    J Antibiot (Tokyo); 2017 Dec; 70(12):1087-1096. PubMed ID: 29089600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How Technological Innovation Affect China's Pharmaceutical Smart Manufacturing Industrial Upgrading.
    Wang S; Chen Y
    J Healthc Eng; 2021; 2021():3342153. PubMed ID: 34868514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial Resistance (AMR).
    Tang KWK; Millar BC; Moore JE
    Br J Biomed Sci; 2023; 80():11387. PubMed ID: 37448857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The development of China's medical biotech industry needs to be driven by innovation.
    Yu Z; Dai Y
    Biotechnol J; 2006 Nov; 1(11):1253-7. PubMed ID: 17068752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reinventing the antimicrobial pipeline in response to the global crisis of antimicrobial-resistant infections.
    Singer AC; Kirchhelle C; Roberts AP
    F1000Res; 2019; 8():238. PubMed ID: 30906539
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.